BlueDil International

🎄 Happy Holidays from BlueDil International! 🎉 As we reflect on #2024, we’re filled with gratitude for an incredible year of achievements and #Partnerships. We have forged long-lasting #Relationships that will continue to thrive over time. We supported patients’ access to #therapies through #ClinicalTrials or #EarlyAccess programs. We have been at the forefront of raising #DiseaseAwareness for rare and ultra-rare diseases, doing our best to improve the #PatientJourney across multiple European countries. We supported our partners with our experience and strategic vision, understanding their needs and delivering tailored solutions. Looking ahead to #2025, we’re excited for new collaborations to start and bring innovative projects to life. Together with our clients and partners, we’ll do our best to create value and drive success for everyone involved. 🚀 Wishing you a season filled with joy, peace, and inspiration. We are looking forward to another year of growth, collaboration, and success! 🥂 #HappyHolidays #ThankYou #Innovation #EU #US #RareDiseases #BlueDil 

📣 Exciting Update from Our Boardroom! At BlueDil International, your success is our priority. ✨ Today, our Board of Directors gathered in Milan to strategize and collaborate on a 2025 filled with exciting new projects. This meeting reflects not only our dedication to innovation and excellence in the #raredisease field but also one of our core values: teamwork. For over 15 years, our Board has worked together, combining experience, vision, and shared goals to ensure that BlueDil International operates as a trusted partner, paving the way for our clients' success. Our unwavering focus is on empowering you to thrive in the highly specialized European #orphandrugs market by creating opportunities, overcoming challenges, and driving meaningful progress. With a clear strategy and strong commitment, we’ll build the future together, one milestone at a time. 🌟 #Leadership #Innovation #Success #Teamwork #Pharma

📢 Exciting Collaboration Announcement❗ We are thrilled to announce the start of a successful partnership between Laboratoires KÔL and BlueDil International! KOL Laboratoires, a French start-up with a global vision, is dedicated to addressing unmet medical needs in #ophthalmology, with a special focus on rare corneal diseases. KOL Laboratoires is committed to bring innovative solutions fitting patients’ needs and BlueDil International is proud to be a trusted #partner in their market expansion. Our support started in Spain and Germany, and we will extend our efforts to Switzerland and Italy in the coming year. Together, we are committed to making a meaningful impact on the rare disease space and driving forward innovation in #corneal care. Looking forward to a successful journey ahead! 🌍 💻Visit our website to discover how we partner 👉 https://lnkd.in/dYd3hCC6 #RareDiseases #CornealPathologies #Innovation #OrphanDrugs 

🤝How do we work in partnership ❓ At BlueDil International, we #partner with our clients to streamline operations and drive success. We coordinate activities across all #European countries of interest, providing a☝️ single point of contact to simplify processes and ensure seamless communication. Our agile and flexible approach evolves with your needs, prioritizing tasks to maximize your investments. Operating with the highest standards and full compliance, our passionate and continuously trained team ensures #excellence at every stage. Discover how we work in partnership through a successful case study with a US biotech start-up 👉 https://lnkd.in/dYd3hCC6 #RareDiseases #Orphandrugs #US #EU #Partnership #PharmaCompanies #Biotech 

You and Your Pipeline are unique ❗ At BlueDil International, we don’t believe that one size fits all. That’s why we provide #tailored solutions from #ClinicalDevelopment to #commercialization, ensuring seamless navigation of the rare diseases #European ecosystem. With over 30 years of #expertise, we support 🤝 European stakeholder engagement, ♟️ strategic planning, and operational execution to 🔓 unleash your #market potential. From building your own networks to implementing Early Access Programs, our services are designed to drive excellence and deliver results🎯. Discover more 👉 https://lnkd.in/du7z5kCw #RareDiseases #OrphanDrug #PharmaCompanies #Biotech #US #EU #StrategicPlanning #EarlyAccess 

🌐 We renewed BlueDil #Website❗   📢 We’re excited to announce the 🚀 launch of our #new website, designed to help you to understand how we can support in growing your presence in the European market. BlueDil International serves as a #VirtualAffiliate for companies developing or marketing #OrphanDrugs for #RareDiseases as they enter or grow in the European market. We work as an extension of your team, representing your trusted partner to ensure a smooth path to success. On our new site, you’ll find more about our areas of #expertise, and the full range of #services we offer. ❓Curious about our previous missions with several #orphantherapies in multiple therapeutic areas? ❓Are you interested in a #success case proving our impact in supporting a US biotech to seize the unique #opportunities and navigate challenges in the #European rare disease ecosystem? ❓ are you interested to schedule a free, customized workshop to analyze together your product’s potential development in the European marketplace? 🔍 Explore Our Website Now ➡️ https://lnkd.in/dYd3hCC6   #MarketEntry #EuropeanPharma #EU #Healthcare #Biotech #Pharmacompanies #US #Medicalaffairs #Network

It is really great to know that BlueDil International is expanding to serve rare disease community. #Rarediseases Maurizio Mioli

📢 𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔! We are pleased to announce that Maurizio Mioli has joined BlueDil International as a Strategic Consultant for Global Business Development & Growth. Based in Cambridge, MA and New York City, Maurizio will be our point of contact in the #USA for all American #pharma companies and #biotech startups looking to expand their orphan drug business in #Europe. ✒️𝑨𝒃𝒐𝒖𝒕 𝑴𝒂𝒖𝒓𝒊𝒛𝒊𝒐 𝑴𝒊𝒐𝒍𝒊: Maurizio Mioli, previously CEO of VMLY&R Health, led a team of 250 professionals dedicated to the international healthcare business across Milan, Zurich, Paris, and Cambridge, MA. With over 30 years in managerial roles, he has launched blockbuster drugs across a wide range of therapeutic areas, including orphan drugs and rare diseases. His experience spans global strategic consulting, promotion, advertising, medical affairs, and education for major international clients like Pfizer, Sanofi, BMS, Novartis and many more. Maurizio teaches Pharmaceutical Marketing & Communication at The University of Pavia (MAMAF Master in Pharmaceutical Marketing) and at ISTUD Business School. 🔗 Contact: maurizio.mioli@bluedil-international.eu 🔗 Connect with Maurizio on LinkedIn: https://lnkd.in/d2MaraPy Join us in welcoming Maurizio to the BlueDil International team! 🌍   𝑨𝒃𝒐𝒖𝒕 𝑩𝒍𝒖𝒆𝑫𝒊𝒍 𝑰𝒏𝒕𝒆𝒓𝒏𝒂𝒕𝒊𝒐𝒏𝒂𝒍: For pharma companies and biotech startups aiming to expand in rare disease operations, BlueDil International is the 𝑽𝑰𝑹𝑻𝑼𝑨𝑳 𝑨𝑭𝑭𝑰𝑳𝑰𝑨𝑻𝑬 for cost-effective business across Europe. We offer the expertise of former 𝑺𝑶𝑩𝑰 𝒆𝒙𝒆𝒄𝒖𝒕𝒊𝒗𝒆𝒔 and a ready-to-start, agile, fully-integrated team tailored to your needs. Our capabilities in Europe (and ex-US territories) include: ➡ Strategic and operational services from clinical development to commercialization ➡ Engagement with key EU stakeholders: Scientific societies, KOLs, HCPs, PAGs, Regulatory Bodies, Payers, and Policymakers ➡ Extensive expertise in rare diseases, orphan therapies, and niche indications At BlueDil International, we provide: ➡ European coordination with a single point of contact ➡ Operational excellence with immediate implementation, compliant with current laws and regulations ➡ Flexible and agile organization adapting to your business needs ➡ Cost-effective, low-risk business approach through prioritized investments ➡ Energetic and passionate dedicated team 🔗 Contact us and follow us on LinkedIn!

📢 𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔! We are pleased to announce that Maurizio Mioli has joined BlueDil International as a Strategic Consultant for Global Business Development & Growth. Based in Cambridge, MA and New York City, Maurizio will be our point of contact in the #USA for all American #pharma companies and #biotech startups looking to expand their orphan drug business in #Europe. ✒️𝑨𝒃𝒐𝒖𝒕 𝑴𝒂𝒖𝒓𝒊𝒛𝒊𝒐 𝑴𝒊𝒐𝒍𝒊: Maurizio Mioli, previously CEO of VMLY&R Health, led a team of 250 professionals dedicated to the international healthcare business across Milan, Zurich, Paris, and Cambridge, MA. With over 30 years in managerial roles, he has launched blockbuster drugs across a wide range of therapeutic areas, including orphan drugs and rare diseases. His experience spans global strategic consulting, promotion, advertising, medical affairs, and education for major international clients like Pfizer, Sanofi, BMS, Novartis and many more. Maurizio teaches Pharmaceutical Marketing & Communication at The University of Pavia (MAMAF Master in Pharmaceutical Marketing) and at ISTUD Business School. 🔗 Contact: maurizio.mioli@bluedil-international.eu 🔗 Connect with Maurizio on LinkedIn: https://lnkd.in/d2MaraPy Join us in welcoming Maurizio to the BlueDil International team! 🌍   𝑨𝒃𝒐𝒖𝒕 𝑩𝒍𝒖𝒆𝑫𝒊𝒍 𝑰𝒏𝒕𝒆𝒓𝒏𝒂𝒕𝒊𝒐𝒏𝒂𝒍: For pharma companies and biotech startups aiming to expand in rare disease operations, BlueDil International is the 𝑽𝑰𝑹𝑻𝑼𝑨𝑳 𝑨𝑭𝑭𝑰𝑳𝑰𝑨𝑻𝑬 for cost-effective business across Europe. We offer the expertise of former 𝑺𝑶𝑩𝑰 𝒆𝒙𝒆𝒄𝒖𝒕𝒊𝒗𝒆𝒔 and a ready-to-start, agile, fully-integrated team tailored to your needs. Our capabilities in Europe (and ex-US territories) include: ➡ Strategic and operational services from clinical development to commercialization ➡ Engagement with key EU stakeholders: Scientific societies, KOLs, HCPs, PAGs, Regulatory Bodies, Payers, and Policymakers ➡ Extensive expertise in rare diseases, orphan therapies, and niche indications At BlueDil International, we provide: ➡ European coordination with a single point of contact ➡ Operational excellence with immediate implementation, compliant with current laws and regulations ➡ Flexible and agile organization adapting to your business needs ➡ Cost-effective, low-risk business approach through prioritized investments ➡ Energetic and passionate dedicated team 🔗 Contact us and follow us on LinkedIn!

🌟 Today is the International #RareDisease Awareness Day! 🌟 🌈 BlueDil International is happy to celebrate the International Rare Disease Awareness Day, which serves as a poignant reminder of the strength, resilience, and unwavering spirit of #patients and families facing these unique challenges. 🌍In our global community, diversity is celebrated in all its forms. Rare diseases, though individually uncommon, collectively affect millions, highlighting the importance of understanding, support, and advocacy. As we commemorate this day, let's amplify our voices, raise awareness, and foster a culture of inclusivity and empathy. #RareAware #caregiveres #pharma #orphandrugs #healthcare #health